Genprex, Inc.
GNPXHealthcare|Biotechnology|US
$2.07
-0.03 (-1.43%)
DCF Value
$168.10
Tangible Book / Share
$31.27
Cash / Share
$32.03
About
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Stock Price
-98.0%(1Y)
1M
-24.7%
3M
-51.5%
6M
-89.2%
YTD
-94.6%
1Y
-97.6%
3Y
-100.0%
5Y
-100.0%
Pipeline Summary
4 total trials4
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 2Terminated: 2
Active Trials (2)
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT05703971Small Cell Lung Cancer Extensive Stage
Phase 1Phase 2Recruiting
Enrollment: 62 participants
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
NCT04486833Carcinoma, Non-Small Cell Lung
Phase 1Phase 2Recruiting
Enrollment: 158 participants
Key Facts
Market Cap$1.0M
Employees13 (-13% YoY)
CEORyan Confer
IPO DateMar 29, 2018
Beta-0.94
52-Week Range$1.71 – $110
Avg Volume222,169
ExchangeNASDAQ
Websitegenprex.com
Ownership
Float95.1%
Shares Outstanding0.5M
Recent Insider Trades
LONGNECKER BRENT MSELL
Apr 14, 20268 shares @ $1.23
LONGNECKER BRENT MSELL
Apr 14, 202610 shares @ $1.23
Berger Mark StanleyTAX W/H
Feb 27, 20267,168 shares @ $2.00
Confer Ryan M.TAX W/H
Feb 27, 20269,330 shares @ $2.00
Moreno Toscano Jose AntonioAWARD
Dec 22, 20259,000 shares
Peers
Recent News
Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
Nov 5, 2026 · prnewswire.com
Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
Nov 4, 2026 · prnewswire.com
Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
Oct 28, 2026 · prnewswire.com
Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging
Oct 21, 2026 · prnewswire.com
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026 · prnewswire.com
Data last updated: Nov 9, 2026, 04:12 AM